Actively Recruiting
Phase 2 Study of Ubamatamab With or Without REGN7075 in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer
Led by Regeneron Pharmaceuticals · Updated on 2026-07-22
300
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying two drugs, ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer NSCLC. They are also evaluating sarilumab to understand if it can help manage immune-related side effects caused by ubamatamab. This study focuses on how well ubamatamab and REGN7075 work, the side effects they might cause, their levels in the blood, and whether the body makes antibodies that might reduce ubamatamabs effectiveness. Participants will receive ubamatamab alone or combined with REGN7075 according to the study protocol. Sarilumab will be assessed for its role in managing immune side effects. The study has multiple experimental arms and uses a randomized design to compare these treatments. The study period extends up to five years to thoroughly assess outcomes and safety. During the study, participants will have their cancer measured by scans such as CT or MRI to track tumor response using RECIST criteria. Researchers will monitor side effects, antibody development against the study drugs, and drug levels in the blood over time. Safety and effectiveness will be followed for up to five years, with regular assessments to evaluate how the treatments perform and their impact on participants.
CONDITIONS
Brief Title
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
